Ligand validation:8SMD

OJC: (2R,3R,3aS,5S,6R,7S,8R,11R,13S,15aR)-2-(6-amino-9H-purin-9-yl)-3,6,7,11,13-pentahydroxyoctahydro-2H,5H,11H,13H-5,8-epoxy-11lambda~5~,13lambda~5~-furo[2,3-g][1,3,5,9,2,4]tetraoxadiphosphacyclotetradecine-11,13-dione

OJC is a Ligand Of Interest in 8SMD designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
8SMD_OJC_B_201	83%	31%	0.109	0.969	1.44	1.33	7	5	0	0	100%	1
8SMD_OJC_A_201	80%	30%	0.118	0.966	1.43	1.38	7	6	2	0	100%	1
8KBE_OJC_B_201	73%	51%	0.14	0.969	0.74	1.13	2	3	0	0	100%	1
8KBF_OJC_A_201	67%	40%	0.14	0.947	0.66	1.65	-	6	3	0	100%	0.97
7UXS_OJC_A_501	99%	63%	0.06	0.988	0.6	0.8	-	1	0	0	100%	1
8SMF_OJC_A_101	93%	32%	0.076	0.97	1.3	1.4	5	6	0	0	100%	1
8KBL_OJC_A_201	43%	48%	0.219	0.943	0.8	1.2	-	5	0	0	100%	0.5

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.